Rectal Neuroendocrine Tumor
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the rectum. 
Rectal neuroendocrine tumors most frequently harbor alterations in SF3B1, FLT4, USP9X, SETD2, and ROS1 .
SF3B1 Mutation, FLT4 Mutation, SETD2 Mutation, ROS1 Mutation, and NOTCH1 Mutation are the most common alterations in rectal neuroendocrine tumor .
There are 2 clinical trials for rectal neuroendocrine tumor, of which 2 are open and 0 are completed or closed. Of the trials that contain rectal neuroendocrine tumor as an inclusion criterion, 2 are phase 2 (2 open).
SSTR2 is the most frequent gene inclusion criterion for rectal neuroendocrine tumor clinical trials .
Cabozantinib, lanreotide, and pembrolizumab are the most common interventions in rectal neuroendocrine tumor clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.